Jean-Francois Geschwind

List of Publications by Year
in descending order

85 papers	3,978 citations	101543 36 h-index	123424 61 g-index
86 all docs	86 docs citations	86 times ranked	4501 citing authors

#	Article	IF	Citations
1	Radioembolization with 90Y Microspheres: Angiographic and Technical Considerations. CardioVascular and Interventional Radiology, 2007, 30, 571-592.	2.0	232
2	Transcatheter Intraarterial Therapies: Rationale and Overview. Radiology, 2011, 259, 641-657.	7.3	206
3	Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion. CardioVascular and Interventional Radiology, 2016, 39, 334-343.	2.0	198
4	Role of Diffusion-Weighted Imaging in Estimating Tumor Necrosis After Chemoembolization of Hepatocellular Carcinoma. American Journal of Roentgenology, 2003, 181, 708-710.	2.2	172
5	How I Do It: Cone-Beam CT during Transarterial Chemoembolization for Liver Cancer. Radiology, 2015, 274, 320-334.	7.3	140
6	Predicting Treatment Response to Intra-arterial Therapies for Hepatocellular Carcinoma with the Use of Supervised Machine Learningâ€"An Artificial Intelligence Concept. Journal of Vascular and Interventional Radiology, 2018, 29, 850-857.e1.	0.5	124
7	Recently elucidated energy catabolism pathways provide opportunities for novel treatments in hepatocellular carcinoma. Expert Review of Anticancer Therapy, 2004, 4, 449-457.	2.4	122
8	TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON. Radiology, 2016, 279, 630-640.	7.3	109
9	Functional MRI Evaluation of Tumor Response in Patients with Neuroendocrine Hepatic Metastasis Treated with Transcatheter Arterial Chemoembolization. American Journal of Roentgenology, 2008, 190, 67-73.	2.2	108
10	Lack of Response after Initial Chemoembolization for Hepatocellular Carcinoma: Does It Predict Failure of Subsequent Treatment?. Radiology, 2012, 265, 115-123.	7.3	102
11	Intraprocedural C-Arm Dual-Phase Cone-Beam CT: Can It Be Used to Predict Short-term Response to TACE with Drug-eluting Beads in Patients with Hepatocellular Carcinoma?. Radiology, 2013, 266, 636-648.	7.3	99
12	Radiologic-Pathologic Analysis of Contrast-enhanced and Diffusion-weighted MR Imaging in Patients with HCC after TACE: Diagnostic Accuracy of 3D Quantitative Image Analysis. Radiology, 2014, 273, 746-758.	7.3	98
13	Quantitative and Volumetric European Association for the Study of the Liver and Response Evaluation Criteria in Solid Tumors Measurements: Feasibility of a Semiautomated Software Method to Assess Tumor Response after Transcatheter Arterial Chemoembolization. Journal of Vascular and Interventional Radiology, 2012, 23, 1629-1637.	0.5	93
14	Liver-Directed Therapy for Hepatic Metastases in Patients Undergoing Pancreaticoduodenectomy. Annals of Surgery, 2010, 252, 142-148.	4.2	86
15	Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach. Radiology, 2016, 278, 275-284.	7.3	85
16	Radioembolisation for liver metastases: Results from a prospective 151 patient multi-institutional phase II study. European Journal of Cancer, 2013, 49, 3122-3130.	2.8	82
17	C-arm cone-beam computed tomography in interventional oncology: technical aspects and clinical applications. Radiologia Medica, 2014, 119, 521-532.	7.7	81
18	⁹⁰Y Radioembolization of Colorectal Hepatic Metastases Using Glass Microspheres: Safety and Survival Outcomes from a 531-Patient Multicenter Study. Journal of Nuclear Medicine, 2016, 57, 665-671.	5.0	79

#	Article	IF	Citations
19	Glyceraldehyde-3-Phosphate Dehydrogenase: A Promising Target for Molecular Therapy in Hepatocellular Carcinoma. Oncotarget, 2012, 3, 940-953.	1.8	79
20	A ketogenic diet increases transport and oxidation of ketone bodies in RG2 and 9L gliomas without affecting tumor growth. Neuro-Oncology, 2016, 18, 1079-1087.	1.2	72
21	Reâ€evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an International Expert Panel. Liver International, 2014, 34, 174-183.	3.9	68
22	Comparing the Detectability of Hepatocellular Carcinoma by C-Arm Dual-Phase Cone-Beam Computed Tomography During Hepatic Arteriography With Conventional Contrast-Enhanced Magnetic Resonance Imaging. CardioVascular and Interventional Radiology, 2012, 35, 97-104.	2.0	66
23	Intrahepatic Cholangiocarcinoma Treated with Local-Regional Therapy: Quantitative Volumetric Apparent Diffusion Coefficient Maps for Assessment of Tumor Response. Radiology, 2012, 264, 285-294.	7.3	60
24	Early survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver. European Radiology, 2015, 25, 1993-2003.	4.5	58
25	Anticancer efficacy of the metabolic blocker 3-bromopyruvate: specific molecular targeting. Anticancer Research, 2013, 33, 13-20.	1.1	55
26	Adjunctive Use of C-Arm CT May Eliminate Technical Failure in Adrenal Vein Sampling. Journal of Vascular and Interventional Radiology, 2007, 18, 1102-1105.	0.5	54
27	Neuroendocrine Liver Metastasis Treated by Using Intraarterial Therapy: Volumetric Functional Imaging Biomarkers of Early Tumor Response and Survival. Radiology, 2013, 266, 502-513.	7.3	54
28	Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization. European Radiology, 2017, 27, 526-535.	4.5	54
29	Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model. European Radiology, 2017, 27, 4995-5005.	4.5	54
30	Radiofrequency Ablation and Chemoembolization for Hepatocellular Carcinoma. Cancer Journal (Sudbury, Mass), 2008, 14, 117-122.	2.0	53
31	Semiautomatic Volumetric Tumor Segmentation for Hepatocellular Carcinoma. Academic Radiology, 2013, 20, 446-452.	2.5	51
32	Identifying Staging Markers for Hepatocellular Carcinoma before Transarterial Chemoembolization: Comparison of Three-dimensional Quantitative versus Nonâ€“three-dimensional Imaging Markers. Radiology, 2015, 275, 438-447.	7.3	48
33	Systemic Delivery of Microencapsulated 3-Bromopyruvate for the Therapy of Pancreatic Cancer. Clinical Cancer Research, 2014, 20, 6406-6417.	7.0	47
34	Uveal Melanoma Metastatic to the Liver: The Role of Quantitative Volumetric Contrast-Enhanced MR Imaging in the Assessment of Early Tumor Response after Transarterial Chemoembolization. Translational Oncology, 2014, 7, 447-455.	3.7	41
35	Imaging Biomarkers of Tumor Response in Neuroendocrine Liver Metastases Treated with Transarterial Chemoembolization: Can Enhancing Tumor Burden of the Whole Liver Help Predict Patient Survival?. Radiology, 2017, 283, 883-894.	7.3	38
36	Quantitative Assessment of Lipiodol Deposition after Chemoembolization: Comparison between Cone-Beam CT and Multidetector CT. Journal of Vascular and Interventional Radiology, 2013, 24, 1837-1844.	0.5	37

#	Article	IF	Citations
37	Comparison of Semi-automatic Volumetric VX2 Hepatic Tumor Segmentation from Cone Beam CT and Multi-detector CT with Histology in Rabbit Models. Academic Radiology, 2013, 20, 115-121.	2.5	37
38	Intraprocedural 3D Quantification of Lipiodol Deposition on Cone-Beam CT Predicts Tumor Response After Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma. CardioVascular and Interventional Radiology, 2015, 38, 1548-1556.	2.0	37
39	Three-dimensional Evaluation of Lipiodol Retention in HCC after Chemoembolization. Academic Radiology, 2014, 21, 393-399.	2.5	33
40	Assessing tumor response after loco-regional liver cancer therapies: the role of 3D MRI. Expert Review of Anticancer Therapy, 2015, 15, 199-205.	2.4	33
41	Validation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra-arterial Therapy. Clinical Gastroenterology and Hepatology, 2017, 15, 746-755.e4.	4.4	33
42	Have we finally found the ultimate staging system for HCC?. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 334-336.	17.8	32
43	Theranostic application of lipiodol for transarterial chemoembolization in a VX2 rabbit liver tumor model. Theranostics, 2019, 9, 3674-3686.	10.0	28
44	Final analysis of GIDEON (Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma) Tj ETQq0 0 0 rgBT /Overlock 10 Tf in pts with liver dysfunction.. Journal of Clinical Oncology, 2013, 31, 4126-4126.	1.6	28
45	Transarterial Chemoembolization for the Treatment of Advanced-Stage Hepatocellular Carcinoma. Journal of Gastrointestinal Surgery, 2016, 20, 2002-2009.	1.7	27
46	Deregulation of energy metabolism promotes antifibrotic effects in human hepatic stellate cells and prevents liver fibrosis in a mouse model. Biochemical and Biophysical Research Communications, 2016, 469, 463-469.	2.1	27
47	Preclinical Benefit of Hypoxia-Activated Intra-arterial Therapy with Evofosfamide in Liver Cancer. Clinical Cancer Research, 2017, 23, 536-548.	7.0	27
48	Radiologic-pathologic analysis of quantitative 3D tumour enhancement on contrast-enhanced MR imaging: a study of ROI placement. European Radiology, 2016, 26, 103-113.	4.5	26
49	Evaluating tumors in transcatheter arterial chemoembolization (TACE) using dual-phase cone-beam CT. Minimally Invasive Therapy and Allied Technologies, 2011, 20, 276-281.	1.2	25
50	Neuroendocrine tumor liver metastases treated with yttrium-90 radioembolization. Contemporary Clinical Trials, 2016, 50, 143-149.	1.8	25
51	3D Quantitative tumour burden analysis in patients with hepatocellular carcinoma before TACE: comparing single-lesion vs. multi-lesion imaging biomarkers as predictors of patient survival. European Radiology, 2016, 26, 3243-3252.	4.5	24
52	Targeting glucose metabolism in cancer: a new class of agents for loco-regional and systemic therapy of liver cancer and beyond?. Hepatic Oncology, 2016, 3, 19-28.	4.2	23
53	Multimodality Imaging of Ethiodized Oilâ€“loaded Radiopaque Microspheres during Transarterial Embolization of Rabbits with VX2 Liver Tumors. Radiology, 2016, 279, 741-753.	7.3	22
54	Delayed-Phase Cone-Beam CT Improves Detectability of Intrahepatic Cholangiocarcinoma During Conventional Transarterial Chemoembolization. CardioVascular and Interventional Radiology, 2015, 38, 929-936.	2.0	20

#	Article	IF	Citations
55	Which Criteria Applied in Multi-Phasic CT Can Predict Early Tumor Response in Patients with Hepatocellular Carcinoma Treated Using Conventional TACE: RECIST, mRECIST, EASL or qEASL?. CardioVascular and Interventional Radiology, 2018, 41, 433-442.	2.0	19
56	Can C-Arm Cone-Beam CT Detect a Micro-Embolic Effect After TheraSphere Radioembolization of Neuroendocrine and Carcinoid Liver Metastasis?. Cancer Biotherapy and Radiopharmaceuticals, 2013, 28, 459-465.	1.0	18
57	Occurrence of a Multimeric High-Molecular-Weight Glyceraldehyde-3-phosphate Dehydrogenase in Human Serum. Journal of Proteome Research, 2015, 14, 1645-1656.	3.7	18
58	Pre- and Postoperative Clinical Care of Patients Undergoing Interventional Oncology Procedures: A Comprehensive Approach to Preventing and Mitigating Complications. Techniques in Vascular and Interventional Radiology, 2006, 9, 113-124.	1.0	16
59	How I Do It. Academic Radiology, 2015, 22, 527-533.	2.5	16
60	Multimodality 3D Tumor Segmentation in HCC Patients Treated with TACE. Academic Radiology, 2015, 22, 840-845.	2.5	16
61	Detection of acute myocardial ischemia using first-pass dynamics of MnDPDP on inversion recovery echoplanar imaging. Journal of Magnetic Resonance Imaging, 1999, 9, 209-214.	3.4	15
62	Metabolic perturbation sensitizes human breast cancer to NK cell-mediated cytotoxicity by increasing the expression of MHC class I chain-related A/B. OncoImmunology, 2015, 4, e991228.	4.6	15
63	Interventional oncology: new options for interstitial treatments and intravascular approaches. Journal of Hepato-Biliary-Pancreatic Sciences, 2010, 17, 405-406.	2.6	14
64	Intraarterial therapies for primary liver cancer: state of the art. Expert Review of Anticancer Therapy, 2013, 13, 1157-1167.	2.4	12
65	Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization. Journal of Visualized Experiments, 2013, , 50795.	0.3	12
66	Irinotecan-Eluting 75â€“150-Î¼m Embolics Lobar Chemoembolization in Patients with Colorectal Cancer Liver Metastases: A Prospective Single-Center Phase I Study. Journal of Vascular and Interventional Radiology, 2018, 29, 1646-1653.e5.	0.5	12
67	Intra-arterial therapies for liver cancer: assessing tumor response. Expert Review of Anticancer Therapy, 2017, 17, 119-127.	2.4	11
68	Three-Dimensional Quantitative Assessment of Uterine Fibroid Response after Uterine Artery Embolization Using Contrast-Enhanced MR Imaging. Journal of Vascular and Interventional Radiology, 2015, 26, 670-678.e2.	0.5	10
69	Renal Cell Carcinoma Metastatic to the Liver: Early Response Assessment after Intraarterial Therapy Using 3D Quantitative Tumor Enhancement Analysis. Translational Oncology, 2016, 9, 377-383.	3.7	10
70	Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma. Journal of Visualized Experiments, 2018, , .	0.3	10
71	Combination of intra-arterial therapies and sorafenib: Is there a clinical benefit?. Radiologia Medica, 2014, 119, 476-482.	7.7	7
72	Image quality improvements in C-Arm CT (CACT) for liver oncology applications: Preliminary study in rabbits. Minimally Invasive Therapy and Allied Technologies, 2013, 22, 297-303.	1.2	6

#	Article	IF	Citations
73	Three-Dimensional Quantitative Assessment of Lesion Response to MR-guided High-Intensity Focused Ultrasound Treatment of Uterine Fibroids. Academic Radiology, 2015, 22, 1199-1205.	2.5	6
74	The impact of antiangiogenic therapy combined with Transarterial Chemoembolization on enhancement based quantitative tumor response assessment in patients with hepatocellular carcinoma. Clinical Imaging, 2017, 46, 1-7.	1.5	6
75	Interventional Oncology in Hepatocellular Carcinoma. Cancer Journal (Sudbury, Mass), 2016, 22, 365-372.	2.0	5
76	Tumor cells and memory T cells converge at glycolysis. Cancer Biology and Therapy, 2014, 15, 483-485.	3.4	4
77	Is the pathway of energy metabolism modified in advanced cirrhosis?. Journal of Hepatology, 2014, 61, 452.	3.7	4
78	Automatic bone removal for 3D TACE planning with C-arm CBCT: Evaluation of technical feasibility. Minimally Invasive Therapy and Allied Technologies, 2016, 25, 162-170.	1.2	2
79	Choice of Intra-arterial Therapy for Hepatocellular Carcinoma: Evidence and Future Horizons. Digestive Disease Interventions, 2017, 01, 105-114.	0.2	1
80	Regional Liver-Directed Therapies for Intrahepatic Cholangiocarcinoma. , 2018, , 111-123.		1
81	Multiparametric quantitative functional MRI for assessing early changes in volumetric functional tumor burden in hepatocellular carcinoma treated by intra-arterial therapies.. Journal of Clinical Oncology, 2012, 30, 4114-4114.	1.6	0
82	Second interim analysis of Global Investigation of Therapeutic Decisions in Unresectable HCC and of its Treatment with Sorafenib (GIDEON): U.S. versus global perspective on patient and disease characteristics, treatment history, and sorafenib use.. Journal of Clinical Oncology, 2012, 30, e14581-e14581.	1.6	0
83	Understanding variations in referral patterns and treatment choices for patients with hepatocellular carcinoma.. Journal of Clinical Oncology, 2013, 31, 293-293.	1.6	0
84	Prospective phase II trial of sorafenib combined with doxorubicin eluting bead-transarterial chemoembolization for patients with unresectable hepatocellular carcinoma: Efficacy analysis.. Journal of Clinical Oncology, 2013, 31, 4124-4124.	1.6	0
85	Multimodality imaging and radiological-pathological analysis of ethiodized oil: Imaging biomarker of tumor necrosis after TACE?. Journal of Clinical Oncology, 2015, 33, TPS503-TPS503.	1.6	0